Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9594 posts found.

money-2180330_960_720

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology

June 20, 2025 Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …
News

Celltrion opens new UK headquarters in Uxbridge to drive long-term growth

June 19, 2025 Research and Development Corporate, Pharmacy, biosimilar medicines, celltrion

Celltrion, focused on the development of biosimilar medicines, has officially opened its new UK headquarters in the Charter Building, Uxbridge, …
News
handshake

KFSHRC and Germfree to launch first modular ATMP manufacturing campus in Saudi Arabia

June 19, 2025 Medical Communications, Research and Development Advanced Therapy Medicinal Product manufacturing, BIO 2025, Corporate, King Faisal Specialist Hospital & Research Centre, Saudi Arabia, biotechnology development, cell therapies, gene therapies

King Faisal Specialist Hospital & Research Centre (KFSHRC) has announced a landmark partnership with Germfree Laboratories to develop Saudi Arabia’s …
News
AstraZeneca_drug_discovery

Bristol Myers Squibb to present positive new data on lymphoma treatment

June 18, 2025 Medical Communications, Research and Development Bristol Myers Squibbs, CAR T-cell therapy, International Conference on Malignant Lymphoma, Oncology, relapsed or refractory marginal zone lymphoma

Bristol Myers Squibb (BMS) has announced positive results from the TRANSCEND FL phase 2 study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) …
News
lab

Captain T Cell joins Bayer Co.Lab Berlin to accelerate TCR therapies

June 18, 2025 Analytical & Laboratory Services, Business Services, Research and Development Bayer Co.Lab, Bayer Co.Lab Berlin, Captain T Cell, Corporate, T-cell receptor therapy, laboratory services

Captain T Cell, a biotech company developing next-generation T-cell receptor (TCR)-based therapies for solid tumours, has announced its selection for …
News
money_pills_2

EVerZom receives €3m funding from French government to industrialise exosome technology

June 18, 2025 Research and Development BpiFfrance, Corporate, Crohn’s disease, EVerZom, France 2030, French government, age-related disorders, exosome therapy, neurodegenerative disease

EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of …
News

Samra Turajlić appointed director of Cancer Research UK Manchester Institute

June 18, 2025 Medical Communications, Research and Development Cancer Research UK, Cancer Research UK Manchester Institute, Oncology, The Royal Marsden NHS Foundation Trust, University of Manchester, cancer research

Cancer Research UK has announced the appointment of Samra Turajlić as the new director of the Cancer Research UK Manchester …
Appointment

Biotium launches new DNA gel analysis technology

June 17, 2025 Business Services, Research and Development Biotium, Corporate, DNA gel analysis, DNAzure blue nucleic acid gel stain, glo-plate white photoactivation device, life sciences reagents

Biotium has announced the launch of its new glo-plate white photoactivation device, a compact LED-powered light box designed to support …
News
Bowel cancer screening image

Scientists discover reason for resistance to bowel cancer treatment

June 17, 2025 Research and Development Cancer Research UK, Oncology, The Institute of Cancer Research, bowel cancer, drug resistance

Scientists funded by Cancer Research UK have demonstrated what may cause some treatments to stop working in people living with …
News

Johnson & Johnson presents promising data on leukaemia treatment

June 16, 2025 Medical Communications, Research and Development European Hematology Association, Janssen-Cilag, Johnson & Johnson, Oncology, chronic lymphocytic leukaemia, clinical trial

Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology …
News

Roche advances treatment for Parkinson’s disease

June 16, 2025 Research and Development Neurology, Parkinson's disease, Roche, clinical trials, neurodegenerative disease

Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s …
News
lab

Bristol Myers Squibb reports positive results for psoriatic arthritis treatment

June 13, 2025 Medical Communications, Research and Development European Alliance of Associations for Rheumatology, Rheumatology, bristol myers squibb, clinical trial, psoriatic arthritis

Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly …
News

EpiEndo publishes new data supporting glasmacinal’s potential in COPD

June 13, 2025 Medical Communications, Research and Development Chronic Diseases, EpiEndo Pharmaceuticals, Fraunhofer Institute for Toxicology and Experimental Medicine, antimicrobial resistance, chronic obstructive pulmonary disease (COPD), lung disease

EpiEndo Pharmaceuticals has announced the publication of three peer-reviewed articles in Pulmonary Pharmacology and Therapeutics, highlighting the therapeutic potential of …
News

PL BioScience appoints Oliver Dick as chief technology officer

June 12, 2025 Clinical trials supplies & documentation logistics, Manufacturing and Production, Research and Development Corporate, Devices, Human Platelet Lysate, PL Bioscience, animal-free cell culture, life sciences

PL BioScience, a German life sciences company specialising in the production and development of human platelet lysate (HPL) for cell …
Appointment
handshake

Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases

June 12, 2025 Manufacturing and Production, Mergers and Acquisitions, Research and Development Chiesi Group, Key2Brain, Neurology, Rare Diseases, lysosomal storage disorders, neurodegenerative disease, partnership, ultra-rare disease

Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development of two blood-brain barrier (BBB)-crossing …
News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026